1. A Novel Prognostic Scoring Model for Myelodysplastic Syndrome Patients With SF3B1 Mutation
- Author
-
Liya Ma, Bin Liang, Huixian Hu, Wenli Yang, Shengyun Lin, Lihong Cao, Kongfei Li, Yuemin Kuang, Lihong Shou, Weimei Jin, Jianping Lan, Xingnong Ye, Jing Le, Huyi Lei, Jiaping Fu, Ying Lin, Wenhua Jiang, Zhiying Zheng, Songfu Jiang, Lijuan Fu, Chuanyong Su, XiuFeng Yin, Lixia Liu, Jiayue Qin, Jie Jin, Shenxian Qian, Guifang Ouyang, and Hongyan Tong
- Subjects
Myelodysplastic syndrome (MDS) ,SF3B1 mutation ,RUNX1 ,EZH2 ,Ras ,prognostic scoring model ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
The outcomes of myelodysplastic syndrome (MDS) patients with SF3B1 mutation, despite identified as a favorable prognostic biomarker, are variable. To comprehend the heterogeneity in clinical characteristics and outcomes, we reviewed 140 MDS patients with SF3B1 mutation in Zhejiang province of China. Seventy-three (52.1%) patients diagnosed as MDS with ring sideroblasts (MDS-RS) following the 2016 World Health Organization (WHO) classification and 118 (84.3%) patients belonged to lower risk following the revised International Prognostic Scoring System (IPSS-R). Although clonal hematopoiesis-associated mutations containing TET2, ASXL1 and DNMT3A were the most frequent co-mutant genes in these patients, RUNX1, EZH2, NF1 and KRAS/NRAS mutations had significant effects on overall survival (OS). Based on that we developed a risk scoring model as IPSS-R×0.4+RUNX1×1.1+EZH2×0.6+RAS×0.9+NF1×1.6. Patients were categorized into two subgroups: low-risk (L-R, score 1.4) group. The 3-year OS for the L-R and H-R groups was 91.88% (95% CI, 83.27%-100%) and 38.14% (95% CI, 24.08%-60.40%), respectively (P
- Published
- 2022
- Full Text
- View/download PDF